AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

AstraZeneca and Bristol Myers Squibb are reportedly in preliminary merger talks, according to CNBC — a significant reversal from AstraZeneca's decade-long strategy of avoiding major acquisitions. The reports have already moved share prices and reignited debate over pharmaceutical industry consolidation.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton